Detection of Mycobacterium tuberculosis Rifampicin Resistance Conferred by Borderline rpoB Mutations: Xpert MTB/RIF is Superior to Phenotypic Drug Susceptibility Testing

被引:11
|
作者
Xia, Hui [1 ]
Song, Yuanyuan [1 ]
Zheng, Yang [1 ]
Wang, Shengfen [1 ]
Zhao, Bing [1 ]
He, Wencong [1 ]
Liu, Dongxin [2 ]
Ou, Xichao [1 ]
Zhou, Yang [1 ]
Zhao, Yanlin [1 ]
机构
[1] Chinese Ctr Dis Control & Prevent, Natl Ctr TB Control & Prevent, 155 Changbai Rd, Beijing, Peoples R China
[2] Shenzhen Third Peoples Hosp, Natl Clin Res Ctr Infect Dis, Inst Hepatol, Shenzhen, Peoples R China
来源
关键词
Mycobacterium tuberculosis; rifampicin; borderline resistance; phenotypic drug susceptibility test; TOOL;
D O I
10.2147/IDR.S358301
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: To compare the ability of detection of borderline rifampicin resistance in Mycobacterium tuberculosis between molecular assay and phenotypic drug susceptibility tests. Methods: Fifty-seven isolates with His445Leu, Asp435Tyr, Leu452Pro, Leu430Pro, His445Asn, Ile491Phe, and His445Ser mutations in rpoB gene identified by whole-genome sequencing conferring borderline rifampicin resistance were included. Molecular-based Xpert MTB/RIF, phenotypic Lowenstein-Jensen (L-J) medium-based drug susceptibility test (DST) with a critical concentration of 40.0 mu g/mL and minimal inhibitory concentration (MIC) assay were performed to detect borderline rifampicin resistance. Results: When using Xpert MTB/RIF, 48/57 (84.2%) isolates exhibited resistance to rifampicin. 25/57 (43.9%) and 33/57 (57.9%) isolates showed rifampicin resistance by L-J medium-based DST with 4 and 6 weeks of incubation, respectively. 30/57 (52.6%) and 40/57 (70.2%) strains were resistant to rifampicin by MIC method at cutoff values of 1.0 and 0.5 mu g/mL, respectively. The detection rate of rifampicin resistance of Xpert MTB/RIF was significantly higher than that of phenotypic methods (p < 0.001). Of the 57 isolates with borderline rpoB mutations, 5 (8.8%) had MICs of 0.25 or 0.12 mu g/mL, 22 (38.6%) had MICs of 0.5 mu g/mL or 1.0 mu g/mL, and 30 (52.6%) other isolates showed MICs >= 2.0 mu g/mL. Conclusion: Molecular-based Xpert MTB/RIF showed superior ability to detect borderline rifampicin resistance over phenotypic DST methods. Extending the incubation time of L-J DST or lowering the cutoff value of the MIC method can improve borderline rifampicin resistance detection.
引用
收藏
页码:1345 / 1352
页数:8
相关论文
共 50 条
  • [41] False detection of rifampicin resistance using Xpert® MTB/RIF Ultra assay due to an A451V mutation in Mycobacterium tuberculosis
    Fitzgibbon, Margaret M.
    Roycroft, Emma
    Sheehan, Gerard
    Mc Laughlin, Anne-Marie
    Quintyne, Keith Ian
    Brabazon, Elaine
    O'Meara, Mary
    Flanagan, Peter R.
    Seagar, A-Louise
    Laurenson, Ian F.
    Keane, Joseph
    Rogers, Thomas R.
    JAC-ANTIMICROBIAL RESISTANCE, 2021, 3 (03):
  • [42] The pattern of rpoB gene mutation of Mycobacterium tuberculosis and predictors of rifampicin resistance detected by GeneXpert MTB/RIF assay in Tanzania
    Torokaa, Peter Richard
    Majigo, Mtebe V.
    Kileo, Heledy
    Urio, Loveness
    Mbwana, Mariam R.
    Monah, Mariam C.
    Ntibabara, Sephord Saul
    Kimambo, Jasper
    Seleman, Paschal
    Franklin, Collins
    Balama, Robert
    Kisonga, Riziki M.
    Joachim, Agricola
    PLOS ONE, 2024, 19 (08):
  • [43] Xpert MTB/RIF for Diagnosis of Tuberculosis and Drug Resistance in Indian Children
    Shah, Ira
    Gupta, Yashashree
    INDIAN PEDIATRICS, 2016, 53 (09) : 837 - 838
  • [44] False-positive rifampicin resistance on Xpert® MTB/RIF caused by a silent mutation in the rpoB gene
    Mathys, V.
    van de Vyvere, M.
    de Droogh, E.
    Soetaert, K.
    Groenen, G.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2014, 18 (10) : 1255 - 1257
  • [45] GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis
    Rigouts, Leen
    Keysers, Jelle
    Rabab, Reenaers
    Fissette, Kristina
    van Deun, Armand
    de Jong, Bouke Catherine
    BMC RESEARCH NOTES, 2023, 16 (01)
  • [46] GeneXpert MTB/RIF Ultra performance to detect uncommon rpoB mutations in Mycobacterium tuberculosis
    Leen Rigouts
    Jelle Keysers
    Reenaers Rabab
    Kristina Fissette
    Armand van Deun
    Bouke Catherine de Jong
    BMC Research Notes, 16
  • [47] Detection of Mycobacterium tuberculosis and rifampicin resistance by Xpert® MTB/RIF assay among presumptive tuberculosis patients in Addis Ababa, Ethiopia from 2014 to 2021
    Diriba, Getu
    Alemu, Ayinalem
    Tola, Habteyes Hailu
    Eshetu, Kirubel
    Yenew, Bazezew
    Amare, Misikir
    Dagne, Biniyam
    Mollalign, Hilina
    Sinshaw, Waganeh
    Abebaw, Yeshiwork
    Seid, Getachew
    Tadesse, Mengistu
    Zerihun, Betselot
    Getu, Melak
    Moga, Shewki
    Meaza, Abyot
    Gamtesa, Dinka Fekadu
    Tefera, Zigba
    Wondimu, Amanuel
    Hailu, Michael
    Buta, Bedo
    Getahun, Muluwork
    Kebede, Abebaw
    IJID REGIONS, 2022, 5 : 97 - 103
  • [48] Accuracy of cobas MTB and MTB-RIF/INH for Detection of Mycobacterium tuberculosis and Drug Resistance
    de Vos, Margaretha
    David, Anura
    Duraisamy, Karthickeyan
    Nadarajan, Darshaalini
    Noroc, Ecaterina
    Penn-Nicholson, Adam
    Crudu, Valeriu
    Giri, Sidhartha
    Maurer, Florian P.
    Pati, Sanghamitra
    Stevens, Wendy
    Scott, Lesley
    Turuk, Jyotimayee
    Schumacher, Samuel G.
    Ruhwald, Morten
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (08): : 708 - 718
  • [49] Trends of Mycobacterium tuberculosis and Rifampicin resistance in Northwest Ethiopia: Xpert® MTB/RIF assay results from 2015 to 2021
    Sirak Biset
    Milto Teferi
    Haylemesikel Alamirew
    Biniyam Birhanu
    Awoke Dessie
    Abebe Aschale
    Anmaw Haymanot
    Selamu Dejenie
    Teshager Gebremedhin
    Wondwossen Abebe
    Gashaw Adane
    BMC Infectious Diseases, 24
  • [50] Trends of Mycobacterium tuberculosis and Rifampicin resistance in Northwest Ethiopia: Xpert® MTB/RIF assay results from 2015 to 2021
    Biset, Sirak
    Teferi, Milto
    Alamirew, Haylemesikel
    Birhanu, Biniyam
    Dessie, Awoke
    Aschale, Abebe
    Haymanot, Anmaw
    Dejenie, Selamu
    Gebremedhin, Teshager
    Abebe, Wondwossen
    Adane, Gashaw
    BMC INFECTIOUS DISEASES, 2024, 24 (01)